Molecular mechanisms of target recognition in an innate immune system: Interactions among factor H, C3b, and target in the alternative pathway of human complement

Journal of Immunology

Volumn 164, Issue 9, 2000, Pages 4742-4751

  Pangburn, Michael K ^a   Pangburn, Kerry L W ^a   Koistinen, Vesa ^b   Meri, Seppo ^b   Sharma, Ajay K ^c  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H;

ANIMAL CELL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RABBIT; REGULATORY MECHANISM;

EID: 0034194259     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.9.4742     Document Type: Article

References (74)

1. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50.
2. Carroll, M. C. 1998. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16:545.
3. Hoffmann, J. A., F. C. Kafatos, C. A. Janeway, Jr., and R. A. B. Ezekowitz. 1999. Phylogenetic perspectives in innate immunity. Science 284:1313.
4. Fearon, D. T. 1997. Seeking wisdom in innate immunity. Nature 388:323.
5. Liszewski, M. K., T. C. Farries, D. M. Lublin, I. A. Rooney, and J. P. Atkinson. 1996. Control of the complement system. Adv. Immunol. 61:201.
6. Sahu, A., T. R. Kozel, and M. K. Pangburn. 1994. Specificity of the thioester-containing site of human C3 and its significance to complement activation. Biochem. J. 302:429.
7. Marques, M. B., D. L. Kasper, M. K. Pangburn, and M. R. Wessels. 1992. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect. Immun. 60:3986.
8. Meri, S., and M. K. Pangburn. 1990. Discrimination between activators and non-activators of the alternative pathway of complement: regulation via a sialic acid/ polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA 87:3982.
9. Pangburn, M. K. 1989. Analysis of the mechanism of recognition in the complement alternative pathway using C3b-bound low molecular weight polysaccharides. J. Immunol. 142:2759.
10. Pangburn, M. K. 1989. Analysis of recognition in the alternative pathway of complement: effect of polysaccharide size. J. Immunol. 142:2766.
11. Pangburn, M. K., and H. J. Müller-Eberhard. 1978. Complement C3 convertase: cell surface restriction of βIH control and generation of restriction on neuraminidase treated cells. Proc. Natl. Acad. Sci. USA 75:2416.
12. Pangburn, M. K., D. C. Morrison, R. D. Schreiber, and H. J. Müller-Eberhard. 1980. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J. Immunol. 124:977.
13. Horstmann, R. D., M. K. Pangburn, and H. J. Müller-Eberhard. 1985. Species specificity of recognition by the alternative pathway of complement. J. Immunol. 134:1101.
14. Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J. Exp. Med. 146:22.
15. Fearon, D. T. 1978. Regulation by membrane sialic acid of βIH-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75:1971.
16. Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. USA 74:1683.
17. Kazatchkine, M. D., D. T. Fearon, J. E. Silbert, and K. F. Austen. 1979. Surface-associated heparin inhibits zymosan-induced activation of the human alternative pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J. Exp. Med. 150:1202.
18. Okada, N., T. Yasuda, and H. Okada. 1982. Restriction of alternative complement pathway activation by sialosylglycolipids. Nature 299:261.
19. Grossman, N., and L. Leive. 1984. Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length. J. Immunol. 132:376.
20. Liang-Takasaki, C. J., N. Grossman, and L. Leive. 1983. Salmonellae activate complement differentially in the alternative pathway depending on their lipopolysaccharide O-antigen. J. Immunol. 130:1867.
21. Vukajlovich, S. W., J. Hoffmann, and D. C. Morrison. 1987. Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathways. Mol. Immunol. 24:319.
22. Joiner, K. A. 1988. Complement evasion by bacteria and parasites. Annu. Rev. Microbiol. 42:201.
23. Carreno, M. P., D. Labarre, F. Maillet, M. Jozefowicz, and M. D. Kazatchkine. 1989. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur. J. Immunol. 19:2145.
24. Wessels, M. R., C. E. Rubens, V.-J. Benedi, and D. L. Kasper. 1989. Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc. Natl. Acad. Sci. USA 86:8983.
25. Grossman, N., S. B. Svenson, L. Leive, and A. A. Lindberg. 1990. Salmonella O antigen-specific oligosaccharide-octyl conjugates activate complement via the alternative pathway at different rates depending on the structure of the O antigen. Mol. Immunol. 27:859.
26. Washburn, R. G., B. J. Bryant-Varela, N. C. Julian, and J. E. Bennett. 1991. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol. Immunol. 28:465.
27. Cooper, N. R. 1991. Complement evasion strategies of microorganisms. Immunol. Today 12:327.
28. Smith, H., J. A. Cole, and N. J. Parsons. 1992. The sialylation of gonococcal lipopolysaccharide by host factors: a major impact on pathogenicity. FEMS Microbiol. Lett. 79:287.
29. Wetzler, L. M., K. Barry, M. S. Blake, and E. C. Gotschlich. 1992. Gonococcal lipopolysaccharide sialylation prevents complement-dependent killing by immune sera. Infect. Immun. 60:39.
30. Horstmann, R. D. 1992. Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation. Infect. Immun. 60:721.
31. Pangburn, M. K. 1998. The alternative pathway: activation and regulation. In The Complement System, 2nd Ed. K. Rother and G. O. Till, eds. Springer-Verlag, New York, p. 93.
32. Pangburn, M. K., R. D. Schreiber, and H. J. Müller-Eberhard. 1983. C3b deposition during activation of the alternative complement pathway and the effect of deposition of the activating surface. J. Immunol. 131:1930.
33. Young, B. J., and T. R. Kozel. 1993. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61:2966.
34. Atkinson, J. P., T. J. Oglesby, D. White, E. A. Adams, and M. K. Liszewski. 1991. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin. Exp. Immunol. 86:27.
35. Devine, D. V. 1991. The regulation of complement on cell surfaces. Transfus. Med. Rev. 5:123.
36. Grossman, N., K. A. Joiner, M. M. Frank, and L. Leive. 1986. C3b binding, but not its breakdown, is affected by the structure of the O-antigen polysaccharide in LPS from Salmonellae. J. Immunol. 136:2208.
37. Ripoche, J., A. J. Day, T. J. R. Harris, and R. B. Sim. 1988. The complete amino acid sequence of human complement factor H. Biochem. J. 249:593.
38. Alsenz, J., J. D. Lambris, T. F. Schulz, and M. P. Dierich. 1984. Localization of the complement component C3b binding site and the cofactor activity for factor 1 in the 38 kDa tryptic fragment of factor H. Biochem. J. 224:389.
39. Alsenz, J., T. F. Schulz, J. D. Lambris, R. B. Sim, and M. P. Dierich. 1985. Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem. J. 232:841.
40. Pangburn, M. K., M. A. L. Atkinson, and S. Meri. 1991. Localization of the heparin-binding site on complement factor H. J. Biol. Chem. 266:16847.
41. Gordon, D. L., R. M. Kaufman, T. K. Blackmore, J. Kwong, and D. M. Lublin. 1995. Identification of complement regulatory domains in human factor H. J. Immunol. 155:348.
42. Kühn, S., C. Skerka, and P. F. Zipfel. 1995. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H. J. Immunol. 155:5663.
43. Blackmore, T., and D. L. Gordon. 1996. SCR 7 is a major heparin/sialic acid binding site of complement factor H. Mol. Immunol. 33:15 (Abstr.).
44. Sharma, A. K., and M. K. Pangburn. 1996. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc. Natl. Acad. Sci. USA 93:10996.
45. Ram, S., A. K. Sharma, S. D. Simpson, S. Gulati, D. P. McQuillen, M. K. Pangburn, and P. A. Rice. 1998. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187:743.
46. Jokiranta, T. S., J. Hellwage, V. Koistinen, P. F. Zipfel, and S. Meri. 1998. Each of the three binding sites on factor H interacts with a distinct site on C3b. Mol. Immunol. 35:360(Abstr.).
47. Lambris, J. D., D. Avila, J. D. Becherer, and H. J. Müller-Eberhard. 1988. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides. J. Biol. Chem. 263:12147.
48. Kazatchkine, M. D., D. T. Fearon, and K. F. Austen. 1979. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and βIH for cell-bound C3b. J. Immunol. 122:75.
49. Nilsson, L., K. E. Storm, S. Thelin, L. Bagge, J. Hultman, J. Thorelius, and U. Nilsson. 1990. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artificial Organs 14:46.
50. Vidern, V., J. L. Svennevig, E. Fosse, G. Semb, A. Osterud, and T. E. Mollnes. 1992. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J. Thorac. Cardiovasc. Surg. 103:806.
51. Hammer, C. H., G. H. Wirtz, L. Renfer, H. D. Gresham, and B. F. Tack. 1981. Large scale isolation of functionally active components of the human complement system. J. Biol. Chem. 256:3995.
52. Pangburn, M. K. 1987. A fluorimetric assay for native C3: the hemolytically active form of the third component of human complement. J. Immunol. Methods 102:7.
53. Götze, O., and H. J. Müller-Eberhard. 1971. The C3-activator system: an alternative pathway of complement activation. J. Exp. Med. 134:90s.
54. Lesavre, P. H., T. E. Hugli, A. F. Esser, and H. J. Müller-Eberhard. 1979. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 123:529.
55. Pangburn, M. K., R. D. Schreiber, and H. J. Müller-Eberhard. 1977. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein βIH for cleavage of C3b and C4b in solution. J. Exp. Med. 146:257.
56. Vogel, C. W., and H. J. Müller-Eberhard. 1982. The cobra venom factor-dependent C3 convertase of human complement. J. Biol. Chem. 257:8292.
57. Estaller, C., W. Schwaeble, M. Dierich, and E. H. Weiss. 1991. Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur. J. Immunol. 21:799.
58. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51.
59. Christopherson, R. I. 1983. Desalting protein solutions in a centrifuge column. Methods Enzymol. 91:278.
60. Pangburn, M. K., R. D. Schreiber, J. S. Trombold, and H. J. Müller-Eberhard. 1983. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J. Exp. Med. 157:1971.
61. Rawal, N., and M. K. Pangburn. 1998. C5 convertase of the alternative pathway of complement: kinetic analysis of the free and surface-bound forms of the enzyme. J. Biol. Chem. 273:16828.
62. Fishelson, Z., and H. J. Müller-Eberhard. 1982. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J. Immunol. 129:2603.
63. Pangburn, M. K., R. D. Schreiber, and H. J. Müller-Eberhard. 1983. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. USA 80:5430.
64. Reid, K. B. M., and A. J. Day. 1989. Structure-function relationships of the complement components. Immunol. Today 10:177.
65. Sim, R. B., and S. J. Perkins. 1989. Molecular modelling of C3 and its ligands. Curr. Top. Microbiol. 153:209.
66. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
67. Discipio, R. G. 1981. The binding of human complement proteins C5, factor B, βIH and properdin to complement fragment C3b on zymosan. Biochem. J. 199: 485.
68. Parker, C. J., P. J. Baker, and W. F. Rosse. 1983. Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes. J. Immunol. 131:2484.
69. Smith, L. C., K. Azumi, and M. Nonaka. 1999. Complement systems in invertebrates: the ancient alternative and lectin pathways. Immunopharmacology 42:107.
70. Schreiber, R. D., M. K. Pangburn, R. G. Medicus, and H. J. Müller-Eberhard. 1980. Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin. Immunol. Immunopathol. 15:384.
71. Kozel, T. R., M. A. Wilson, and W. H. Welch. 1992. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:3122.
72. Mollnes, T. E., J. Riesenfeld, P. Garred, E. Nordstrom, K. Hogasen, E. Fosse, O. Götze, and M. Harboe. 1995. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artificial Organs 19:909.
73. Pruitt, S. K., A. D. Kirk, R. R. Bollinger, H. C. Marsh, Jr., B. H. Collins, J. L. Levin, J. R. Mault, J. S. Heinle, S. Ibrahim, and A. R. Rudolph. 1994. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57:363.
74. Discipio, R. G. 1992. Ultrastructures and interactions of complement factors H and I. J. Immunol. 149:2592.